2024-09-05 07:53:15
A drug called ubrogepant can be useful to prevent the onset of migraine when the first symptoms appear, such as: sensitivity to light and sound, fatigue, dizziness, or pain and stiffness in the neck.
When taken at the first signs of a migraine, before the headache starts, a drug called ubrogepant can be effective in helping people with migraine continue with their daily lives with few or no symptoms, such as new research published in ‘Neurology’.
The study focuses on people with migraine who can tell when an attack is about to occur, because of early symptoms such as sensitivity to light and sound, fatigue, neck pain or stiffness, or dizziness.
Ubrogepant is a peptide receptor antagonist related to the calcitonin gene or an inhibitor of CGRP, a protein that plays an important role in the migraine process.
“Migraine is one of the most common diseases in the world, but many people who suffer from it do not receive treatment or say they are not satisfied with it.”says the author of the study, Dr. Richard B. Liptonof the Albert Einstein College of Medicine in the Bronx, New York, and a member of the American Academy of Medicine.
“Improving attention to the first signs of migraine, even before the headache starts, can be the key to improving results. “Our findings are encouraging and suggest that ubrogepant can help people with migraine work regularly and continue with their daily lives.”he added.
The study included 518 people who had suffered from migraine for at least a year and who had experienced between two and eight migraine attacks per month in the three months before the study. All participants often experienced symptoms of a migraine that would start in the next few hours. Participants were asked to treat two seizures over a two-month period.
The researchers divided the participants into two groups. The first group received a placebo for the first set of pre-migraine symptoms, followed by 100 milligrams (mg) of ubrogepant for the second set of symptoms. The second group took ubrogepant for the first event and placebo for the second.
The participants assessed the limitations in their activity in their diary using a scale ranging from zero to five, where 0 means “no limit at all, can do everything”; 1, “partial”; 2, “a little”; 3, “very limited”; or 4, “very limited.”
Twenty-four hours after taking the drug or placebo, 65 percent of people taking ubrogepant reported feeling better. “there is no limit: they can do everything” or “a little”compared to 48 percent of those who took the placebo.
The researchers found that two hours after taking the drug, people who took the drug were 73 percent more likely to report that “they have no disabilities and are able to work normally” than those who took a placebo.
“Based on our findings, treatment with ubrogepant may enable people with migraine who experience early warning signs before the onset of migraine to treat migraine attacks quickly in their early stages and continue with their lives. their daily lives with little anxiety and infirmities”Lipton said. “This can lead to a better quality of life for those living with migraine”he added.
Lipton noted that participants showed that, based on headache warning symptoms, they could reliably predict the onset of upcoming migraines. These findings apply to those with co-dependent symptoms.
One limitation of the study is that participants recorded their symptoms and medication use in electronic diaries, so some people may not have recorded all the information accurately. LDB (SyM)
#study #effectiveness #drug #stop #migraine #symptoms #Health #Medicine